HanAll BioPharma's large-scale technology export of its bio new drug was chosen as one of the “Top 10 Science & Technology News of the Year” of the Republic of Korea in 2017, which was selected by the Korean Federation of Science and Technology Societies (KOFST).
HanAll BioPharma has succeeded in exporting technology and rights of HL161, an autoimmune disease therapeutic antibody drug under phase 1 clinical study, to Roivant Sciences in Switzerland for USD 502.5 million in December. This is the first large-scale technology export case of antibody drug developed in Korea.
HanAll BioPharma’s new antibody drug for autoimmune disease therapy is currently attracting attention as a treatment for severe autoimmune diseases such as myasthenia gravis, pemphigus, chronic thrombocytopenia, neuromyelitis optica, polyneuropathy and lupus nephritis that have no distinct therapeutic agent.
KOFST announced “Top 10 Science & Technology News of the Year” selected after reflecting results of three times of review at the selection committee (Chairperson Lee Myung-Chul, President of the Korean Academy of Science and Technology, and 30 others) and online and mobile voting of 6,396 people in science and technology fields and the general public.
Regarding HanAll BioPharma’s entry into the global market, the KOFST said, “It is a case of technology export of domestically developed antibody drug for more than KRW 500 billion.” “With the research and development of companies related to new bio-drugs and biosimilars, generic versions of expensive biologic drugs, continues to perform well in the global market,” it added.
"The research and development achievements of biosimilars related to biopharmaceuticals and generic drugs continue to perform well in the global market."